non hodgkin's lymphoma survival rate | The survival rate for patients for presenting the non Hodgkin lymphoma have improved over the past decade

The survival rate for patients for presenting the non Hodgkin lymphoma have improved over the past decade


Five and ten-year survival rate for patients with non-Hodgkin Lymphoma appear to have increased of the 1990s at the beginning of the 21st century, according to a report in the issue of March 10, Archives of internal medicine.
The Non Hodgkin Lymphoma includes several cancers of the immune system that occur in approximately 20.4 on all 100,000 people, according to the background information in the article. The application of regulation for the condition has changed rapidly in recent years.

Dianne Pulte, M.D., Center of cancer German, Heidelberg, and colleagues analyzed data from the control program, epidemiology and of results final (seer) of the National Institute of the Cancer of the United States. Survival rates were based planned biennial time periods between 1990 and 2004 the where patients were diagnosed with lymphoma non-Hodgkin, as well as by age group (15-44, 45-54, 55-64, 65-74 and 75 years old or older) , sex, race, location of tumor (i.e. If the disease was nodal [in the lymph nodes] or extranodal [in one site other than the lymph nodes]) and histological subtype (to classify tumors as) high-grade or low-grade).

"Relative survival General and five years increased from 50.4 percent to 66.8 percent, and the 10-year relative survival increased from 39.4 percent to 56.3 percent between 1990 to 1992 and 2002 to 2004," the authors write. The ' improvements were more pronounced during younger than 45 years of patients (over 26.8 and plus 27.1 points for five and ten-year survival, respectively), but improvements were seen in all the age groups, in both sexes, in the. nodal and extranodal and disease in low-grade and high-grade disease. The improvements in the prognosis were less in black patients than white patients, particularly in younger black patients. »

Two factors may explain these improvements, the authors note. "We're advances in treatment that occurred between 1990 and 2004, in particular the introduction of treatment of antibody for lymphoma non Hodgkin," they write. "Application of regulations with antibody treatment and chemotherapy has sustainable expectance in many cases, but if and how many times this extension represents a true cure is still unknown." In addition, improvements in HIV treatment have reduced the cases of lymphomas not Hodgkiniens of related to HIV and also made them easier to deal with.

"Our estimates of the long-term survival in patients with non-Hodgkin Lymphoma obtained by the method of analysis of the 2002 to 2004 period are much higher than the previously available estimates of survival, which. concern largely on patients diagnosed during the 1990s,"the authors conclude. "The timely release of improvements in survival in patients, stage managers, researchers, and the public is essential."